3.93 USD
▲+0.10+2.61%
盘后 3.91 -0.51%
2026-11-19
市值
$261.81M
市盈率
—
EPS
-1.06
股息率
—
52 周区间
1.31 – 7.80
成交量
3.13M
Beta
2.02
目标价
13.75
52W 低 1.3152W 高 7.80
价格走势
公司简介
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Bo...